Sonoma pharmaceuticals and emc pharma announce department of defense dapa registration for microcyn(r) rx products

Boulder, co / accesswire / january 25, 2023 / sonoma pharmaceuticals, inc. (nasdaq:snoa), a global healthcare leader developing and producing patented microcyn® technology based stabilized hypochlorous acid (hocl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care, today announced that microcyn® rx products have received a distribution and pricing agreement (dapa) for distribution by the defense logistics agency (dla). the dapa enables our partner, emc pharma, to enter into distribution agreements for microcyn® rx products with federal customers.
SNOA Ratings Summary
SNOA Quant Ranking